solid
organ
transplant
ever
evolv
field
signific
advanc
manag
recipi
solid
organ
transplant
includ
enhanc
immun
suppress
antimicrobi
prophylaxi
atrisk
patient
order
increas
number
avail
organ
turn
save
live
transplant
wait
list
donor
pool
must
continu
expand
donor
reflect
divers
us
popul
increas
number
donor
born
resid
travel
underdevelop
area
world
area
geograph
restrict
infect
donor
expos
pathogen
potenti
transmit
recipi
donor
organ
addit
newer
techniqu
identifi
mani
pathogen
may
transmit
donor
transplant
recipi
final
highprofil
report
sever
donorderiv
infect
heighten
awar
donorderiv
infect
like
contribut
increas
recognit
chapter
incid
method
identif
prevent
manag
unexpect
donorderiv
infect
review
often
donor
expect
transmit
infect
ie
cmv
donor
seroposit
recipi
seroneg
inform
known
transplant
team
posttranspl
case
inform
lead
intervent
reduc
incid
sever
transmit
diseas
review
elsewher
text
unit
state
organ
procur
transplant
network
optn
polici
set
framework
minim
track
case
donorderiv
infect
transmiss
polici
includ
languag
defin
donor
enhanc
risk
diseas
transmiss
tabl
need
obtain
special
inform
consent
use
organ
donor
known
transmiss
diseas
risk
factor
diseas
transmiss
need
develop
local
polic
screen
recipi
transmit
diseas
posttranspl
appropri
need
report
proven
potenti
diseas
transmiss
polici
also
defin
requir
live
deceas
donor
screen
http
optntransplanthrsagovgovernancepolici
council
europ
also
develop
similar
guidanc
document
updat
regularli
provid
similar
guidanc
donor
screen
risk
mitig
http
likewis
european
union
nation
govern
establish
law
direct
regul
function
outsid
unit
state
experi
demonstr
donor
withdocu
infect
pose
risk
transmiss
infect
donor
recipi
risk
transmiss
vari
ie
low
risk
appropri
treat
document
bacteri
mening
naegleria
enceph
high
risk
activ
hiv
infect
fact
risk
diseas
transmiss
requir
sever
key
step
organ
procur
organ
must
inform
recipi
center
potenti
transmiss
infectionth
recipi
center
must
assess
benefit
transplant
outweigh
risk
diseas
transmissionth
recipi
center
must
obtain
special
inform
consent
use
organ
donor
recogn
risk
diseas
transmissionth
recipi
center
must
develop
plan
treat
recipi
appropri
prevent
diseas
transmiss
monitor
recipi
evid
transmit
infectionspecif
detail
key
step
discuss
greater
detail
later
chapter
donor
document
infect
instead
engag
behavior
characterist
place
donor
increas
risk
infect
pathogen
hiv
hepat
b
hepat
c
turn
transmit
recipi
donor
defin
optn
us
public
health
servic
ph
donor
increas
risk
diseas
transmiss
term
increas
risk
donor
ph
updat
guidanc
relat
increas
risk
donor
guidanc
adopt
standard
transplant
system
global
updat
guidelin
refin
prior
guidanc
take
account
current
knowledg
epidemiolog
hiv
hbv
hcv
commun
limit
contemporari
screen
practic
tabl
guidelin
focus
three
key
core
recommend
screen
singl
standard
valid
tool
collect
donor
medic
social
histori
although
mani
us
opo
util
uniform
donor
risk
assess
interview
tool
http
wwwaatborgdraidocu
although
live
deceas
donor
consid
equal
risk
guidelin
live
donor
abl
provid
histori
histori
deceas
donor
obtain
friend
rel
individu
may
know
fine
detail
donor
social
situat
eg
mother
colleg
student
live
home
guidelin
recogn
limit
place
donor
incomplet
donor
histori
increas
risk
categori
risk
may
present
unrecognizedth
guidelin
newli
recommend
donor
screen
serolog
nucleic
acid
test
nat
hepat
c
regardless
risk
factor
increas
risk
donor
screen
hiv
nat
addit
routin
serolog
present
time
serolog
mandat
hepat
b
screen
although
serolog
assess
includ
hepat
b
surfac
antigen
hbsag
allow
direct
detect
viru
addit
nat
screen
serolog
allow
increas
detect
acut
infect
nat
decreas
length
time
initi
infect
abil
test
detect
infect
refer
window
period
figur
guidelin
also
recogn
live
donor
may
continu
engag
behavior
place
increas
risk
diseas
transmiss
screen
donat
guidelin
recommend
live
donor
screen
close
donat
procedur
possibl
exceed
day
feasibl
recommend
demonstr
clinic
consent
patient
receiv
organ
patient
risk
factor
understand
risk
agre
receiv
organ
base
risk
assess
special
inform
consent
increas
risk
donor
organ
use
mandat
policyfollowup
test
perhap
one
import
recommend
ph
guidelin
need
posttranspl
test
recipi
receiv
increas
risk
donor
organ
ensur
diseas
transmiss
occur
earli
test
may
affect
outcom
transmiss
identifi
avail
effect
therapi
introduc
sooner
transmiss
recommend
includ
hiv
nat
combin
assay
hcv
nat
hbv
nat
hbsag
month
posttranspl
hbv
serolog
month
posttranspl
includ
hepat
b
surfac
antibodi
hepat
b
core
antibodi
either
hbv
nat
hbsag
howev
data
show
posttranspl
test
reliabl
perform
use
assay
directli
detect
viru
posttranspl
period
critic
serolog
may
reliabl
recipi
frequent
fail
seroconvert
due
transmit
infect
case
hcv
transmiss
identifi
unit
state
exampl
recipi
seroneg
nat
posit
even
test
nearli
year
posttranspl
guidelin
help
defin
donor
increas
risk
diseas
transmiss
identifi
donor
higher
likelihood
hiv
hbv
hcv
infect
review
exist
data
clearli
demonstr
risk
hiv
hcv
infect
vari
significantli
risk
behavior
tabl
given
enhanc
risk
import
realiz
patient
may
acquir
infect
nat
window
period
time
infect
nat
detect
infect
see
nat
decreas
risk
diseas
transmiss
residu
risk
remain
clearli
demonstr
three
recent
transmiss
hcv
donor
engag
nonmed
drug
use
prior
death
neg
donor
nat
test
date
limit
prospect
collect
data
incid
donorderiv
infect
prior
establish
optnunit
network
organ
share
uno
ad
hoc
diseas
transmiss
advisori
committe
dtac
system
place
prospect
collect
data
estim
incid
donorderiv
infect
data
avail
publish
case
report
underreport
dtac
common
initi
recent
data
show
substanti
increas
number
report
tabl
figur
era
current
screen
follow
unexpect
transmiss
report
numer
bacteri
speci
includ
gramposit
cocci
gramneg
rod
ehrlichia
chaffeensi
legionella
syphili
tuberculosi
candida
spp
histoplasmosi
zygomycosi
aspergillu
spp
scedosporiosi
coccidioidomycosi
cytomegaloviru
hiv
hbv
hcv
adenoviru
coxsackieviru
human
tlymphotrop
viru
lymphocyt
choriomening
viru
relat
arenaviru
west
nile
viru
wnv
rabi
schistosomiasi
strongyloid
trypanosoma
cruzi
microsporidiosi
balamuthia
spp
avail
data
us
french
system
donorderiv
diseas
transmit
less
transplant
approxim
recipi
die
transmit
diseas
sever
key
point
learn
data
collect
date
confirm
bacteri
transmiss
commonli
report
transmiss
like
repres
common
form
diseas
transmiss
confirm
case
bacteria
transmiss
involv
highli
resist
gramposit
gramneg
infect
seri
histor
studi
abdomin
organ
thorac
organ
appear
contamin
bacteri
pathogen
time
procur
use
periop
antibiot
reduc
risk
diseas
transmiss
although
underrecognit
underreport
bacteri
transmiss
like
given
high
rate
contamin
increas
preval
highli
resist
bacteria
hospit
global
bacteri
transmiss
increas
time
dilig
import
among
transplant
team
although
attempt
estim
risk
donorderiv
infect
none
consid
accur
formal
screen
process
identifi
potenti
transmiss
issu
underrecognit
underreport
transmiss
remain
critic
requir
current
uno
polici
everyon
care
transplant
recipi
consid
potenti
donor
origin
infect
particularli
earli
posttranspl
plan
place
report
concern
local
opo
uno
organ
vigil
system
similar
optnuno
patient
safeti
system
contribut
rapid
commun
effici
time
commun
associ
lower
rate
recipi
advers
event
includ
death
region
without
organ
vigil
system
establish
formal
system
recent
requir
eu
direct
improv
patient
outcom
potenti
improv
safeti
transplant
system
donor
undergo
rang
f
screen
includ
review
donor
medic
social
histori
physic
examin
donor
organ
attent
paid
test
perform
donor
blood
risk
stratifi
donor
mandat
screen
blood
tradit
focus
detect
antibodi
antigen
present
donor
typic
use
enzymelink
immunosorb
assay
elisa
infecti
diseas
screen
molecular
screen
method
use
nat
hiv
hbv
hcv
screen
implement
us
organ
procur
organ
optn
polici
updat
mandat
hcv
nat
deceas
donor
screen
hiv
nat
screen
increas
risk
organ
donor
indirect
elisa
use
detect
antibodi
ie
hbcab
sandwich
elisa
use
detect
antigen
ie
hbsag
indirect
elisa
http
wwwpahoorghqindexphp
optioncomtop
viewarticl
known
antigen
fix
bottom
plastic
surfac
usual
multiwel
plate
serum
ad
antibodi
react
antigen
present
bind
antigen
plate
wash
detect
antibodi
usual
antiigg
antiigm
antibodi
conjug
substratespecif
enzym
appli
well
wash
substrat
appli
convert
enzym
conjug
detector
antibodi
typic
result
colorimetr
chang
intens
chang
provid
semiquantit
measur
presenc
antigenspecif
antibodi
detect
antigen
sandwich
elisa
use
captur
antibodi
one
specif
antigen
interest
bound
plate
patient
serum
appli
antigen
present
bound
captur
assay
plate
wash
antigenspecif
antibodi
sandwich
detect
antibodi
substrat
ad
result
colorimetr
chang
read
method
rel
rapid
turnaround
time
subject
signific
risk
contamin
usual
done
either
automat
machin
minim
technic
skill
discuss
clear
challeng
serolog
assay
detect
infect
earlier
antibodi
creat
nat
use
screen
certain
infect
nat
refer
wide
rang
polymeras
chang
reaction
pcr
transcript
amplif
test
tma
branch
dna
test
pcr
wide
use
test
primer
code
complimentari
region
pathogenspecif
gene
interest
select
rna
virus
rna
first
revers
transcrib
creat
complementari
dna
cdna
base
rna
templat
point
pcr
rna
dna
virus
sourc
nucleic
acid
mix
select
primer
dna
polymeras
deoxynucleosid
triphosph
buffer
materi
initi
step
activ
polymeras
denatur
step
melt
dna
two
singl
strand
primer
may
anneal
extens
elong
occur
repeat
cycl
proceed
amplifi
presenc
gene
interest
presenc
dna
detect
one
sever
way
realtim
pcr
fluoresc
dye
use
intercal
doublestrand
dna
quantit
detect
target
dna
nat
challeng
longer
turnaround
time
serolog
test
greater
technic
expertis
perform
test
risk
contamin
may
result
falseposit
test
result
especi
lowvolum
laboratori
individu
infect
viral
infect
typic
local
replic
viru
subsequ
viremia
see
figur
period
time
initi
infect
detect
viremia
refer
eclips
period
viremia
present
immun
system
recogn
viru
produc
neutral
antibodi
compon
viru
period
initi
infect
first
detect
antibodi
refer
window
period
transmiss
hiv
hcv
donor
recipi
report
uno
eclips
serolog
window
period
window
period
differ
viru
shorten
time
improv
serolog
test
abl
detect
antibodi
earlier
initi
infect
tabl
unfortun
even
antibodi
form
may
challeng
detect
antibodi
first
donor
requir
transfus
blood
blood
product
receiv
larg
volum
fluid
replet
intravascular
compart
may
dilut
concentr
antibodi
antigen
viral
particl
limit
detect
process
refer
hemodilut
number
way
hemodilut
assess
one
method
current
consid
gold
standard
simpl
guidelin
test
may
less
reliabl
donor
receiv
greater
l
blood
crystalloid
within
h
blood
sampl
greater
l
crystalloid
within
h
sampl
adult
recommend
strict
pediatr
donor
second
donor
may
lose
serolog
responseto
certain
infect
time
particularli
immunosuppress
thirdli
infant
donor
serolog
test
may
detect
presenc
matern
antibodi
without
activ
infect
child
type
donor
affect
test
well
gener
two
type
donor
live
deceas
donor
major
differ
donor
type
potenti
qualiti
donor
histori
time
frame
donor
screen
may
take
place
case
live
donat
actual
donor
interview
may
allow
collect
accur
medic
behavior
histori
qualiti
medic
behavior
histori
challeng
deceas
donat
histori
obtain
friend
famili
member
may
know
medic
behavior
limit
contact
donor
historian
often
clinic
circumst
lead
death
deceas
donor
may
contribut
donor
found
accur
histori
preced
event
may
limit
likewis
donor
may
undergon
extens
resuscit
andor
prolong
hospit
affect
donor
screen
infecti
hemodilut
discuss
introduct
infect
time
transfus
may
signific
time
frame
initi
screen
organ
donat
case
live
donor
consider
repeat
test
closer
time
transplant
consid
current
polici
recommend
hiv
hbv
hcv
screen
live
donor
perform
within
day
transplant
time
allow
donor
may
treat
potenti
transmiss
infect
latent
tb
prior
transplant
decreas
transmiss
risk
lastli
period
time
initi
evalu
transplant
allow
one
screen
live
donor
risk
factor
contract
bloodborn
viral
infect
hiv
hbv
hcv
increas
risk
live
donor
defin
public
health
servic
guidelin
counsel
abstain
increas
risk
behavior
repeat
nat
serolog
test
period
time
similar
window
period
viru
interest
consid
minim
risk
occult
transmiss
previous
state
screen
potenti
organ
donor
critic
identifi
pathogen
transmit
recipi
current
optn
polici
requir
screen
done
certain
pathogen
see
tabl
enhanc
cultur
obtain
set
hospit
h
current
polici
requir
sputum
gram
stain
descript
sputum
lung
donor
requir
collect
bal
specimen
cultur
although
bacteri
cultur
frequent
done
opo
viral
fungal
mycobacteri
cultur
typic
obtain
decemb
nat
requir
hcv
screen
donor
hiv
screen
increas
risk
donor
posit
nat
result
suggest
activ
viremia
appropri
measur
need
place
appropri
consent
prophylaxi
followup
recipi
transmiss
event
virem
donor
organ
use
neg
nat
rule
infect
although
may
suggest
lower
risk
transmiss
chaga
diseas
caus
parasit
endem
region
central
south
america
sinc
test
chaga
requir
blood
donor
seropreval
unit
state
known
signific
geograph
variabl
recogn
avail
us
guidelin
recommend
target
cruzi
screen
potenti
donor
born
mexico
central
america
south
america
given
high
rate
falseposit
result
donor
initi
reactiv
result
confirm
second
test
guidelin
suggest
program
consid
transplant
kidney
liver
cruziinfect
donor
inform
consent
recipi
recommend
use
heart
transplant
infect
donor
recipi
cruziinfect
donor
monitor
posttranspl
pcrbase
screen
institut
antitrypanosom
treatment
recipi
infect
detect
low
true
risk
diseas
transmiss
endem
fungal
infect
risk
appear
highest
coccidioidomycosi
like
risk
donor
transmiss
well
recipi
reactiv
diseas
coccidioidomycosi
endem
sonoran
desert
southwest
unit
state
northwest
mexico
addit
central
south
america
donor
recipi
endem
region
screen
seroposit
enzym
immunoassay
eia
complement
fixat
cf
immunodiffus
id
donor
recipi
seroposit
prophylaxi
fluconazol
typic
mg
initi
month
follow
mg
daili
recommend
increas
number
donorderiv
strongyloid
transmiss
unit
state
like
secondari
larg
pool
potenti
donor
latent
infect
increas
use
steroid
donor
mainten
strongyloid
endem
tropic
subtrop
region
world
seroposit
may
exceed
locat
histor
high
rate
strongyloid
document
appalachia
southeastern
unit
state
current
guidelin
recommend
routin
screen
donor
endem
region
strongyloid
igg
live
donor
treat
ivermectin
daili
two
separ
day
prior
donat
wherea
recipi
deceas
donor
posit
strongyloid
antibodi
receiv
ivermectin
posttranspl
us
blood
donor
screen
wnv
presenc
antibodiesto
wnv
predict
risk
infect
present
prior
wnv
infect
relat
flavivirus
detect
viru
blood
molecular
test
predict
increas
risk
transmiss
although
transmiss
neg
nat
survey
reveal
opo
current
test
donor
wnv
pcr
typic
perform
test
season
viru
would
predict
donor
servic
area
univers
test
may
associ
loss
organ
net
loss
life
transplant
candid
effect
screen
avoid
use
donor
unexplain
enceph
unexplain
mental
statu
chang
unfortun
donor
may
complet
asymptomat
carri
infect
sinc
transmiss
neuropathogen
malign
associ
patient
unexplain
enceph
avoid
donor
prudent
gener
donor
test
util
restrict
nat
donor
blood
period
time
wnv
case
region
donor
resid
use
donor
wnv
serolog
test
urin
wnv
recommend
time
donor
screen
critic
minim
risk
posttranspl
infecti
complic
recipi
screen
may
contribut
prevent
donorderiv
diseas
transmiss
tabl
particularli
import
cmv
case
potenti
heart
recipi
toxoplasmosi
risk
diseas
prophylact
plan
frequent
determin
donor
recipi
serostatu
addit
potenti
recipi
screen
tuberculosi
use
medic
histori
assess
potenti
exposur
prior
test
prior
treatment
radiolog
examin
baselin
chest
radiograph
test
latent
tuberculosi
use
either
ppd
mm
cutoff
posit
tbspecif
releas
assay
quantiferontb
gold
cellesti
inc
victoria
australia
potenti
recipi
also
screen
either
clinic
serolog
histori
exposur
varicellazost
viru
allow
pretranspl
vaccin
unexpos
candid
recipi
may
expos
pathogen
region
endem
care
travel
resid
histori
obtain
potenti
recipi
determin
special
test
indic
chaga
diseas
reactiv
asymptomat
latent
affect
recipi
sinc
chaga
endem
throughout
much
mexico
central
south
america
consider
screen
potenti
candid
affect
countri
consid
sinc
approv
serolog
test
lack
specif
confirmatori
test
recommend
patient
confirm
posit
serolog
screen
evalu
expert
chaga
diseas
proceed
transplant
strongyloid
parasit
infect
endem
tropic
subtrop
region
world
infect
may
remain
latent
initi
infect
risk
potenti
lethal
hyperinfect
immunosuppress
patient
particularli
receiv
steroid
reactiv
associ
mortal
well
describ
set
solid
organ
transplant
result
serolog
strongyloid
andor
test
stool
ova
parasit
consid
atrisk
transplant
candid
lastli
center
test
patient
live
area
high
endem
coccidioid
immiti
serolog
exposur
fungu
role
test
recipi
serolog
histoplasmosi
blastomycosi
certain
transplant
candid
may
underli
organ
diseas
predispos
pathogen
warrant
special
especi
true
among
lung
transplant
candid
patient
histori
cystic
fibrosi
may
colon
pathogen
highli
resist
usual
antibiot
regular
screen
cultur
bal
nasal
wash
may
allow
tailor
specif
periop
antibiot
regimen
minim
risk
posttranspl
infect
resist
pathogen
recipi
serolog
strong
driver
pretranspl
vaccin
detail
recommend
transplant
candid
recipi
vaccin
made
elsewher
see
chap
patient
evid
hepat
b
immun
receiv
three
dose
hbv
vaccin
unless
contraind
although
tradit
regimen
vaccin
month
use
center
evid
acceler
regimen
use
doubl
dose
vaccin
day
week
month
may
provid
similar
efficaci
shorter
period
time
serolog
evid
protect
demonstr
hb
antibodi
seroposit
would
potenti
allow
use
coreposit
alon
hbvinfect
organ
protect
recipi
likewis
patient
without
prior
exposur
varicellazost
viru
increas
risk
sever
infect
expos
posttranspl
nonimmun
transplant
candid
vaccin
varicella
unless
contraind
vaccin
lastli
although
lot
data
regard
measl
mump
posttranspl
given
recent
outbreak
diseas
unit
state
abroad
measl
mump
immun
ensur
prior
transplant
especi
candid
born
vaccin
era
organ
donor
unit
state
increas
risk
undetect
hiv
hbv
andor
hcv
increas
risk
donor
ph
guidelin
suggest
even
though
attempt
made
ensur
highest
level
safeti
organ
donor
recipi
select
practic
polici
restrict
consid
clinic
inform
decisionmak
import
part
process
transplant
clinician
patient
data
suggest
may
net
benefit
use
increas
risk
donor
organ
especi
patient
hemodialysi
risk
acquir
infect
alreadi
particularli
screen
use
nat
per
current
optn
polici
addit
donor
diseas
malign
transmiss
risk
identifi
pretranspl
transplant
program
must
explain
risk
obtain
inform
consent
potenti
transplant
recipi
transplant
document
consent
potenti
recipi
medic
record
follow
recipi
deceas
live
donor
organ
develop
potenti
donorderiv
diseas
transplant
polici
also
state
donor
found
increas
risk
transmit
blood
born
pathogen
transplant
program
must
offer
recipi
donor
addit
posttranspl
test
hiv
hepat
c
hepat
b
appropri
everi
transplant
hospit
must
develop
implement
written
protocol
posttranspl
test
well
treatment
prophylaxi
transmiss
diseas
avail
polici
also
requir
host
opo
maintain
blood
specimen
appropri
serolog
nat
avail
deceas
donor
least
year
date
organ
transplant
ensur
sampl
avail
retrospect
test
ph
guidelin
outlin
recipi
increas
risk
donor
organ
follow
recommend
baselin
serolog
drawn
immedi
pretranspl
follow
test
month
posttranspl
hiv
nat
combin
assay
hbv
nat
hbsag
hcv
nat
addit
follow
test
recommend
month
posttranspl
hbsab
hbcab
either
hbv
nat
hbsag
transmiss
without
seroconvers
especi
case
hcv
occur
major
donorderiv
transmiss
date
therefor
posttranspl
test
recipi
increas
risk
donor
organ
must
use
serolog
molecular
method
document
diseas
transmiss
must
report
local
opo
uno
warrant
evalu
well
referr
manag
transmit
infect
current
number
limit
recognit
potenti
donorderiv
transmiss
event
often
singl
donor
provid
organ
recipi
multipl
differ
center
recipi
care
differ
manag
team
center
result
multipl
recipi
may
present
similar
clinic
ill
cluster
ill
goe
unrecogn
likewis
pathogen
commonli
recogn
caus
nosocomi
infect
may
recogn
potenti
donorderiv
infect
final
onset
diseas
may
variabl
sever
individu
may
present
variabl
onset
posttranspl
challeng
recognit
donorderiv
transmiss
overcom
challeng
critic
transplant
center
maintain
high
level
suspicion
donorderiv
infect
earli
infect
unexplain
clinic
ill
earli
infect
unexplain
clinic
ill
lead
inquiri
clinic
statu
recipi
easili
done
contact
local
opo
especi
true
patient
unexplain
neurolog
sever
ill
within
first
day
posttransplantdevelop
plan
report
concern
potenti
donorderiv
infect
transmiss
plan
includ
local
contact
transplant
center
opo
concern
potenti
donorderiv
infect
transmiss
likewis
import
consid
transplant
center
risk
manag
polici
determin
other
within
institut
need
alert
plan
also
includ
opo
contact
center
question
statu
recipi
base
queri
gener
center
found
appoint
specif
surgeon
transplant
infecti
diseas
consult
earli
point
contact
facilit
clear
transmiss
dataprovid
time
feedback
patient
inform
request
oposeek
outsid
expertis
local
health
depart
uno
diseas
transmiss
advisori
committe
center
diseas
control
offic
blood
organ
tissu
safeti
group
advis
optim
test
help
collect
appropri
specimen
may
provid
insight
similar
case
allow
local
center
make
inform
treatment
decis
previous
discuss
organ
donor
current
screen
serolog
hiv
cmv
ebv
hbv
hcv
also
hcv
nat
current
requir
optn
polici
although
recent
pass
hiv
organ
polici
equiti
act
allow
research
perform
use
organ
donor
infect
use
organ
transplant
yet
allow
outsid
research
protocol
unit
state
donor
seroposit
cmv
ebv
univers
use
although
donor
recipi
serolog
statusmay
determin
monitor
prophylaxi
plan
risk
develop
cmv
viremia
diseas
greatest
seroneg
recipi
seroposit
organ
describ
later
text
univers
prophylaxi
preemptiv
therapi
reduc
risk
viremia
diseas
atrisk
patient
develop
posttranspl
lymphoprolif
disord
ptld
describ
particularli
young
ebv
seroneg
recipi
ebv
seroposit
donor
care
monitor
intervent
describ
later
text
may
reduc
risk
ptld
set
current
mandat
donor
screen
hepat
b
includ
detect
hbv
surfac
antigen
hbsag
core
antibodi
hbcab
hbsag
marker
activ
viremia
hbcab
marker
exposur
hepat
b
viru
sinc
hbv
vaccin
contain
hepat
b
surfac
antigen
vaccin
donor
hbv
surfac
antibodi
hbsab
hbcab
hbsag
measur
earli
vaccin
detect
blood
risk
transmiss
hbv
nonimmun
recipi
high
hbsagposit
donor
use
organ
discuss
chapter
hepat
b
although
hbsagposit
donor
may
defer
past
advanc
use
hepat
b
immun
globulin
antihbv
antivir
allow
select
use
organ
donor
isol
hbcab
posit
may
repres
latent
infect
individu
falseposit
result
risk
transmiss
hbv
liver
transplant
recipi
higher
nonliv
recipi
risk
transmiss
hbv
donor
isol
hbcab
estim
less
nonliv
recipi
addit
test
donor
hbcore
igm
hbv
dna
nat
would
stratifi
risk
transmiss
highest
risk
igm
nat
donor
center
use
organ
particularli
patient
vaccin
hepat
b
use
nonimmun
patient
posttranspl
vaccin
often
combin
use
either
antihbv
antivir
prophylaxi
hepat
b
immun
globulin
infus
recipi
especi
liver
recipi
hbsag
hbcab
donor
monitor
close
presenc
activ
viral
replic
expans
therapi
base
result
detect
hcv
antibodiessuggest
prior
infect
hepat
c
infect
hcv
clear
viru
hcv
serolog
test
rel
high
known
falseposit
rate
therefor
use
hcv
nat
donor
screen
allow
differenti
prior
hcv
infect
activ
infect
viremia
use
hcvposit
donor
hcvneg
recipi
current
consid
lifethreaten
situat
howev
hcvposit
donor
organ
consid
hcvinfect
recipi
small
like
clinic
insignific
decreas
found
transplant
graft
patient
surviv
hcv
organ
use
hcvinfect
recipi
offset
concomit
decreas
transplant
wait
list
time
mortal
appear
higher
among
heart
recipi
use
hcv
seroposit
donor
less
frequent
consid
one
concern
relat
infect
recipi
addit
hcv
genotyp
may
less
respons
antivir
therapi
sinc
genotyp
result
typic
known
time
transplant
advent
new
evolv
data
regard
directact
antivir
interferonfre
hcv
regimen
option
treat
hcv
transplant
continu
chang
note
requir
bacteri
screen
organ
donor
blood
urin
cultur
donor
screen
syphili
opo
requir
determin
addit
culturebas
test
conduct
donor
prior
procur
unfortun
current
challeng
donor
declar
deceas
often
discharg
hospit
readmit
new
account
care
opo
procur
cultur
come
posit
laboratori
may
realiz
deceas
patient
becom
donor
inform
opo
donor
result
hospit
may
stop
work
cultur
deceas
patient
result
obtain
lastli
followup
cultur
bacterem
donor
may
avail
time
procur
gener
donor
posit
blood
cultur
may
use
receiv
appropri
antimicrobi
clinic
respons
therapi
often
complet
cours
therapi
given
recipi
posttranspl
transmiss
particularli
virul
organ
describ
donor
bacteremia
candidemiamand
treatment
recipi
minimum
day
appropri
activ
system
therapi
expert
recommend
week
recipi
therapi
receiv
organ
donor
bacterem
nonbacterem
local
infect
site
requir
treatment
transmiss
transmit
organ
plausibl
ie
posit
urinari
cultur
requir
therapi
kidney
recipi
sputum
cultur
requir
therapi
lung
recipi
recipi
unless
bacterem
etc
patient
proven
bacteri
mening
even
bacteremia
organ
safe
use
long
patient
receiv
least
h
appropri
antibiot
antibiot
continu
recipi
donor
bacteri
colon
lung
donor
common
donor
lung
sampl
includ
donor
bronchoscopi
time
lung
transplant
may
allow
direct
antimicrobi
therapi
donor
test
latent
infect
syphili
per
optn
polici
recent
survey
opo
reveal
use
rpr
test
opo
confirm
posit
initi
test
confirmatori
test
high
rate
posit
rpr
result
neg
confirmatori
test
transmiss
syphili
organ
transplant
rare
contraind
organ
donat
recipi
typic
treat
latent
syphili
unknown
durat
weekli
million
unit
dose
benzathin
penicillin
g
lastli
sometim
perfus
transport
media
may
becom
contamin
bacteria
fungi
infect
risk
factor
system
infect
format
mycot
aneurysm
site
vascular
anastamos
full
cours
activ
antibiot
recommend
recipi
minim
risk
transmiss
gener
screen
done
deceas
donor
perform
live
donor
activ
tuberculosi
donor
contraind
donat
deceas
donor
thought
possibl
tuberculosi
organ
use
unless
activ
tb
infect
definit
rule
donortransmit
tb
account
posttranspl
case
tuberculosi
test
tb
done
ppd
place
use
mantoux
method
via
tbspecif
releas
assay
quantiferontb
gold
cellesti
inc
victoria
australia
posit
test
either
method
result
care
assess
activ
diseas
includ
chest
imag
appropri
sputum
andor
urinari
afb
cultur
center
provid
latent
tb
treatment
recipi
organ
donor
decis
individu
transmiss
univers
recipi
receiv
treatment
latent
tb
note
donor
test
promin
recipi
chart
trigger
aggress
evalu
appropri
clinic
present
ie
steril
pyuria
pneumonia
toxoplasmosi
parasit
remain
dormant
predominantli
muscl
tissu
risk
transmiss
greatest
heart
donat
routin
screen
donor
toxoplasmosi
done
mani
opo
polici
requir
serum
procur
time
explant
heart
perform
toxoplasmosi
serolog
recipi
center
posit
serolog
contraind
transplant
set
heart
transplant
donor
recipi
toxoplasma
serostatusmay
affect
prophylact
monitor
strategi
gener
prophylaxi
modifi
nonheart
recipi
toxoplasmosi
seroposit
donor
donorderiv
infect
increasingli
recogn
caus
morbid
mortal
typic
present
earli
posttranspl
period
care
screen
donor
histori
physic
examin
serolog
molecular
test
may
minim
risk
infect
transmiss
imposs
screen
potenti
pathogen
current
screen
practic
clear
limit
result
possibl
donor
origin
consid
earli
infect
patient
atyp
clinic
cours
report
proven
suspect
donorderiv
infect
current
mandat
part
optn
polici
